Patents Assigned to Johannes Gutenberg-Universitat Mainz
  • Individualized vaccines for cancer
    Patent number: 10738355
    Abstract: The present invention relates to the provision of vaccines which are specific for a patient's tumor and are potentially useful for immunotherapy of the primary tumor as well as tumor metastases. In one aspect, the present invention relates to a method for providing an individualized cancer vaccine comprising the steps: (a) identifying cancer specific somatic mutations in a tumor specimen of a cancer patient to provide a cancer mutation signature of the patient; and (b) providing a vaccine featuring the cancer mutation signature obtained in step (a). In a further aspect, the present invention relates to vaccines which are obtainable by said method.
    Type: Grant
    Filed: May 23, 2012
    Date of Patent: August 11, 2020
    Assignees: TRON-Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gGmbH, BioNTech RNA Pharmaceuticals GmbH
    Inventors: Ugur Sahin, Sebastian Kreiter, Mustafa Diken, Jan Diekmann, Michael Koslowski, Cedrik Britten, John Christopher Castle, Martin Lower, Bernhard Renard, Tana Omokoko, Johannes Hendrikus De Graaf
  • Monoclonal antibodies against claudin-18 for treatment of cancer
    Patent number: 10738108
    Abstract: The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLD18, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder.
    Type: Grant
    Filed: September 20, 2017
    Date of Patent: August 11, 2020
    Assignees: Astellas Pharma Inc., TRON-TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ GEMEINNÜTZIGE GMBH
    Inventors: Ugur Sahin, Özlem Türeci, Dirk Usener, Stefan Fritz, Christoph Uherek, Gunda Brandenburg, Harald-Gerhard Geppert, Anja Kristina Schröder, Phillippe Thiel
  • Screening method for the identification of agents capable of activating CD4+CD25+ regulatory T-cells through interactions with the HIV-1 GP120 binding site on CD4
    Patent number: 10729742
    Abstract: The present invention relates specific activation of a regulatory T cell via a specific CD4 epitope and uses thereof, e.g. for the treatment of an autoimmune disease or an allergy or asthma or graft rejection or tolerance induction.
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: August 4, 2020
    Assignee: Universitätsmedizin Der Johannes Gutenberg-Universität Mainz
    Inventors: Franz-Josef Schneider, Christian Becker, Tobias Bopp, Helmut Jonuleit, Edgar Schmitt
  • Stabilization of poly(A) sequence encoding DNA sequences
    Patent number: 10717982
    Abstract: The present invention relates to nucleic acid molecules containing poly (dA:dT) regions which are stabilized in E. coli, methods of propagating such nucleic acid molecules in E. coli, methods of obtaining RNA, peptides or proteins using such nucleic acid molecules and to RNA which is obtained from such nucleic acid molecules and its use. In particular, the poly (dA:dT) regions contain at least one disruption by a sequence not encoding a sequence solely composed of A residues.
    Type: Grant
    Filed: July 6, 2015
    Date of Patent: July 21, 2020
    Assignees: BioNTech RNA Pharmaceuticals GmbH, TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gGmbH
    Inventors: Florian Eberle, Ugur Sahin, Andreas Kuhn, Britta Vallazza, Mustafa Diken
  • Agents for treatment of claudin expressing cancer diseases
    Patent number: 10717780
    Abstract: The present invention provides binding agents that contain n binding domain that is specific for CD3 allowing binding to T cells and a binding domain that is specific for a tumor-associated claudin molecule and methods of using these binding agents or nucleic acids encoding therefor for treating cancer.
    Type: Grant
    Filed: August 30, 2018
    Date of Patent: July 21, 2020
    Assignees: BioNTech AG, Ganymed Pharmaceuticals GmbH, TRON—Translationale Onkologic an der Universitätsmedzin der Johannes Gutenberg-Universität Mainz gemcinnützige GmbH
    Inventors: Ugur Sahin, Ozlem Türeci, Christiane Stadler, Julia Holland, Hayat Bähr-Mahmud, Tim Beissert, Laura Plum, Fabrice Le Gall, Arne Jendretzki, Markus Fiedler
  • Methods and kits for the diagnosis of cancer
    Patent number: 10705089
    Abstract: The present invention relates to methods and kits for the diagnosis, prognosis and/or monitoring of cancer in a patient. The present invention further relates to isolated peptides, panels of isolated peptides and diagnostic devices.
    Type: Grant
    Filed: April 15, 2015
    Date of Patent: July 7, 2020
    Assignees: BioNTech Disgnostics GmbH, TRON-Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gemeinnützige GmbH
    Inventors: Rainer Hipfel, Clara Werner, Andree Rothermel, Ugur Sahin, Yvonne Kuhne
  • RNA molecules encoding cytokine fusion proteins and methods of use thereof
    Patent number: 10669322
    Abstract: The present invention relates to cytokine fusion proteins and to nucleic acid molecules encoding such cytokine fusion proteins. The present invention further relates to cells, non-human organisms, pharmaceutical compositions and kits comprising the cytokine fusion proteins or the nucleic acid molecules encoding them, as well as to their use as medicaments.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: June 2, 2020
    Assignees: BIONTECH RNA PHARMACEUTICALS GMBH, TRON—TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ GGMBH
    Inventors: Ugur Sahin, Friederike Gieseke, Sebastian Kreiter, Mustafa Diken
  • Diagnosis and therapy of cancer involving cancer stem cells
    Patent number: 10604568
    Abstract: The present invention provides methods for diagnosis or treatment of cancer diseases involving cancer stem cells comprising targeting CLDN6. In particular, the present invention provides a method of determining cancer stem cells comprising detecting cells expressing CLDN6, Furthermore, the present invention provides a method of treating or preventing cancer comprising inhibiting and/or eliminating cancer stem cells by administering an antibody having the ability of binding to CLDN6 to a cancer patient.
    Type: Grant
    Filed: July 30, 2014
    Date of Patent: March 31, 2020
    Assignees: BioN Tech AG, TRON-TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ GEMEINNÜTZIGE GMBH, Astellas Pharma Inc.
    Inventors: Ugur Sahin, Ozlem Tureci, Korden Walter, Meike Wagner, Maria Kreuzberg, Sabine Hacker, Stefan Jacobs
  • Monoclonal anti-GT 468 antibodies for treatment of cancer
    Patent number: 10596256
    Abstract: The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing GT468, including tumor-related diseases such as breast cancer, lung cancer, gastric cancer, ovarian cancer, hepatocellular cancer, colon cancer, pancreatic cancer, esophageal cancer, head & neck cancer, kidney cancer, in particular renal cell carcinoma, prostate cancer, liver cancer, melanoma, sarcoma, myeloma, neuroblastoma, placental choriocarcinoma, cervical cancer, and thyroid cancer, and the metastatic forms thereof. In one embodiment, the tumor disease is metastatic cancer in the lung.
    Type: Grant
    Filed: December 21, 2015
    Date of Patent: March 24, 2020
    Assignees: TRON—TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ GEMEINNÜTZIGE GMBH, ASTELLAS PHARMA INC.
    Inventors: Ugur Sahin, Ozlem Tureci, Michael Koslowski, Rita Mitnacht-Kraus
  • RNA Formulation for Immunotherapy
    Publication number: 20200085974
    Abstract: The present invention is in the field of immunotherapy, in particular tumor immunotherapy. The present invention provides pharmaceutical formulations for delivering RNA to antigen presenting cells such as dendrite cells (DCs) in the spleen after systemic administration. In particular, the formulations described herein enable to induce an immune response after systemic administration of antigen-coding RNA.
    Type: Application
    Filed: September 23, 2019
    Publication date: March 19, 2020
    Applicants: BioNTech RNA Pharmaceuticals GmbH, TRON-Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg-Universitat Mainz gG
    Inventors: Ugur Sahin, Heinrich Haas, Sebastian Kreiter, Mustafa Diken, Daniel Fritz, Martin Meng, Lena Mareen Kranz, Kerstin Reuter
  • Particles comprising a shell with RNA
    Patent number: 10576146
    Abstract: The present invention relates to RNA decorated particles such as RNA decorated lipid particles, preferably to RNA decorated liposomes. Further, the present invention relates to a pharmaceutical composition comprising RNA decorated particles such as RNA decorated lipid particles, preferably RNA decorated liposomes. Said pharmaceutical composition is useful for inducing an immune response. It is also useful in a prophylactic and/or therapeutic treatment of a disease involving an antigen. Furthermore, the present invention relates to a method for producing the RNA decorated particles such as RNA decorated lipid particles, preferably RNA decorated liposomes.
    Type: Grant
    Filed: March 15, 2018
    Date of Patent: March 3, 2020
    Assignees: BIONTECH RNA PHARMACEUTICALS GMBH, TRON-TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ
    Inventors: Ugur Sahin, Heinrich Haas, Sebastian Kreiter, Yves Hüsemann, Mustafa Diken, Kerstin Reuter, Hossam Hefesha
  • Tumor vaccination involving a humoral immune response against self-proteins
    Patent number: 10526387
    Abstract: The present invention relates to tumor immunotherapy, in particular to tumor vaccination, using chimeric proteins comprising all or a portion of a hepatitis B virus core antigen protein and an amino acid sequence comprising an epitope derived from the extracellular portion of a tumor-associated antigen. In particular, the present invention provides virus-like particles comprising said chimeric proteins, which are useful for eliciting a humoral immune response in a subject against the tumor-associated antigen, in particular against cells carrying said tumor-associated antigen on their surface, wherein the tumor-associated antigen is a self-protein in said subject.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: January 7, 2020
    Assignees: BIONTECH PROTEIN THERAPEUTICS GMBH, TRON—TRANSLATIONALE ONKOLOGIE AN DER UNIVRESITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ GEMEINNÜTZIGE GMBH
    Inventors: Thorsten Klamp, Ugur Sahin, Ozlem Tureci, Michael Koslowski, Thomas Hiller, Jens Schumacher
  • Rheological blood replacement solution and uses thereof
    Patent number: 10485756
    Abstract: The present invention relates to a polymer solution for use as a rheological blood substitute. The rheological blood replacement solution comprises in its basic composition a water-soluble cellulose polymer with a molecular weight of 100 kDa or greater, polyethylene oxide and a solvent. The rheological blood replacement solution of the invention can be used in a variety of applications, e.g. as blood substitute, calibration agent or reference agent. The blood replacement solution is based on a polymer solution, which can also be used as pharmaceutical composition, e.g. for the prevention or treatment of haemorrhage or shock-related disorders.
    Type: Grant
    Filed: March 21, 2016
    Date of Patent: November 26, 2019
    Assignee: Universitätsmedizin der Johannes Gutenberg-Universität Mainz
    Inventor: John Eckelt
  • Methods for Predicting the Usefulness of Proteins or Protein Fragments for Immunotherapy
    Publication number: 20190178871
    Abstract: The present invention relates to methods for predicting peptides or polypeptides such as T cell epitopes useful for immunotherapy such as for vaccination. In particular, the present invention relates to methods for predicting whether peptides or polypeptides such as tumor-associated antigens or epitopes, in particular tumor-associated neoantigens or neoepitopes, are immunogenic and, in particular, useful for immunotherapy such as for vaccination. The methods of the invention may be used, in particular, for the provision of vaccines which are specific for a patient's tumor and, thus, in the context of personalized cancer vaccines.
    Type: Application
    Filed: May 10, 2017
    Publication date: June 13, 2019
    Applicants: BioNTech RNA Pharmaceuticals GmbH, TRO-Translationable Onkologie an der Unversitatsme dizin der Johannes Gutenberg-Universitat Mainz
    Inventors: Mathias Vormehr, Ugur Sahin, Barbara Schrörs, Martin Löwer, Sebastian Boegel
  • Combination therapy involving antibodies against claudin 18.2 for treatment of pancreatic cancer
    Patent number: 10314890
    Abstract: The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as pancreatic cancer and metastases thereof.
    Type: Grant
    Filed: August 23, 2017
    Date of Patent: June 11, 2019
    Assignees: ASTELLAS PHARMA INC., TRON—TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ GEMEINNUTZIGE GMBH
    Inventors: Ugur Sahin, Ozlem Tureci, Rita Mitnacht-Kraus, Stefan Woll, Stefan Jacobs, Cornelia Heinz
  • Cytokine fusion proteins
    Patent number: 10301368
    Abstract: The present invention relates to cytokine fusion proteins and to nucleic acid molecules encoding such cytokine fusion proteins. The present invention further relates to cells, non-human organisms. pharmaceutical compositions and kits comprising the cytokine fusion proteins or the nucleic acid molecules encoding them, as well as to their use as medicaments.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: May 28, 2019
    Assignees: BIOTECH RNA PHARMACEUTICALS GMBH, TRON-TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ GMBH, UNIVERSITÄT STUTTGART
    Inventors: Ugur Sahin, Friederike Gieseke, Ronald Backer, Sebastian Kreiter, Roland Kontermann, Klaus Pfizenmaier, Sina Fellermaier, Dafne Müller
  • Antibodies for treatment of cancer expressing claudin 6
    Patent number: 10233253
    Abstract: The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLDN6, including tumor-related diseases such as ovarian cancer, lung cancer, gastric cancer, breast cancer, hepatic cancer, pancreatic cancer, skin cancer, malignant melanoma, head and neck cancer, sarcoma, bile duct cancer, cancer of the urinary bladder, kidney cancer, colon cancer, placental choriocarcinoma, cervical cancer, testicular cancer, and uterine cancer.
    Type: Grant
    Filed: March 21, 2016
    Date of Patent: March 19, 2019
    Assignees: GANYMED PHARMACEUTICALS AG, JOHANNES GUTENBERG-UNIVERSITÄT MAINZ
    Inventors: Ugur Sahin, Ozlem Tureci, Michael Koslowski, Korden Walter, Stefan Woll, Maria Kreuzberg, Bernd Hubner, Michael Erdeljan, Michael Weichel
  • Individualized vaccines for cancer
    Patent number: 10155031
    Abstract: The present invention relates to a patient-specific tumor treatment targeting individual expression patterns of tumor antigens, in particular shared tumor antigens, and individual tumor mutations. In one aspect, the present invention relates to a method for preventing or treating cancer in a patient comprising the steps of: (i) inducing a first immune response against one or more tumor antigens in the patient, and (ii) inducing a second immune response against one or more tumor antigens in the patient wherein the second immune response is specific for cancer specific somatic mutations present in cancer cells of the patient.
    Type: Grant
    Filed: November 26, 2013
    Date of Patent: December 18, 2018
    Assignees: BioNTech RNA Pharmaceuticals GmbH, TRON (Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg-Universitat Mainz Gemeinnutzige GmbH
    Inventors: Ugur Sahin, Claudia Paret, Kirsten Vormbrock, Christian Bender, Jan Diekmann
  • Therapy involving antibodies against Claudin 18.2 for treatment of cancer
    Patent number: 10137195
    Abstract: The present invention generally provides a therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, in particular cancer diseases such as gastroesophageal cancer. Data are presented demonstrating that administration of an anti-CLDN18.2 antibody to human patients with gastroesophageal cancer is safe and well-tolerated up to a dose of at least 1000 mg/m2. Furthermore, data are presented demonstrating that the antibody is fully functional in these patients to execute anti-tumor cell effects and evidence for antitumoral activity was obtained.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: November 27, 2018
    Assignees: Ganymed Pharmaceuticals GmbH, TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gGmbH
    Inventors: Ugur Sahin, Özlem Türeci
  • Bifunctional chelating agents based on the 1,4-diazepine scaffold (DAZA) for non-invasive molecular imaging
    Patent number: 10130722
    Abstract: A compound for radio metal complexation includes a chelator and one or more biological targeting vectors TV conjugated to said chelator, wherein the chelator has structure (A) or (B) or (C), based on 1,4-diazepine with groups R1, R2, R3, R4, X1, X2, X3. The compound is particularly suited for complexation of radio-isotopic metals, such as 66Ga(III), 67Ga(III) and 68Ga(III).
    Type: Grant
    Filed: May 14, 2014
    Date of Patent: November 20, 2018
    Assignee: Johannes Gutenberg-Universität Mainz
    Inventors: Frank Rösch, Bradley Peter Waldron, David Parker